Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.65 |
| ▸ | MAOA | P21397 | 8/20 | 0.65 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30823523 | 1.00 | MAOB (0.65) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL578947 | 0.89 | MAOB (0.75) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL1664699 | 0.89 | MAOA (0.75) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL28772016 | 0.85 | MAOB (0.57) | MAOBMAOACYP1A2RAB9ANPC1 | |
| SCHEMBL29690200 | 0.85 | MAOB (0.57) | MAOBMAOACYP1A2RAB9ANPC1 | |
| SCHEMBL1853898 | 0.84 | MAOB (0.69) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL3639311 | 0.84 | NPC1 (0.66) | MAOBMAOARAB9ANPC1TDP1 | |
| SCHEMBL308991 | 0.83 | MAOB (0.72) | MAOBMAOACYP1A2RAB9AMEN1 | |
| SCHEMBL10046165 | 0.83 | MAOB (0.72) | MAOBMAOACYP1A2RAB9AMEN1 | |
| SCHEMBL16406719 | 0.81 | MAOB (0.65) | MAOBMAOACCNB2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255762-A1 | CBL-B INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-3105228-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES AND OBESITY | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-10023544-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-17 | — | — | US | disclosed |
| EP-3105228-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-20160347724-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-01 | — | — | US | disclosed |
| CN-106170487-A | Heterocyclic compounds | 武田药品工业株式会社 | 2016-11-30 | — | — | CN | disclosed |
| US-9428470-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-30 | — | — | US | disclosed |
| WO-2015122188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225354-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225354-A1 | HETEROCYCLIC COMPOUND | MMP2, DPP4, TMPRSS15 | MAOB 730/4885MAOA 514/4885CCNB2 2869/4885 |
| US-20160347724-A1 | HETEROCYCLIC COMPOUND | MMP2, DPP4, TMPRSS15 | MAOB 730/4885MAOA 514/4885CCNB2 2869/4885 |
| US-10023544-B2 | Heterocyclic compound | MMP2, DPP4, TMPRSS15 | MAOB 730/4885MAOA 514/4885CCNB2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.